CONSIDER VYEPTI FOR YOUR PATIENTS LIKE CAROL
Every patient who suffers from migraine has a unique set of challenges to navigate.
This website is intended for US healthcare professionals only.
VYEPTI permanent J-code (J3032) is now available. Learn more
*Episodic migraine was defined as 4 to 14 headache days per month, of which ≥4 were migraine days.1 One month was defined as 28 consecutive days.2
Compliance issues
Increased use of acute medications
Busy, working mother
Fear of self-injection
†Fictitious patient case.
Age: 35 years old
Sex: Female
Diagnosis: Episodic migraine, 17 years
Mean migraine days per month: 11
Comorbidities: Obesity
‡This patient profile may represent some of the healthcare challenges that could be encountered during typical clinical practice. Symptoms and responses to any treatment may vary. As always, use your clinical judgement.
With one 30-minute IV infusion every 12 weeks, VYEPTI has the potential to help some patients overcome challenges associated with migraine.1
VYEPTI is contraindicated in patients with serious hypersensitivity to eptinezumab-jjmr or to any of the excipients. Reactions have included angioedema.
VYEPTI is indicated for the preventive treatment of migraine in adults.
Hypersensitivity reactions: Hypersensitivity reactions, including angioedema, urticaria, facial flushing, and rash, have occurred with VYEPTI in clinical trials. Most hypersensitivity reactions occurred during infusion and were not serious, but often led to discontinuation or required treatment. Serious hypersensitivity reactions may occur. If a hypersensitivity reaction occurs, consider discontinuing VYEPTI, and institute appropriate therapy.
The most common adverse reactions (≥2% and at least 2% or greater than placebo) in the clinical trials for the preventive treatment of migraine were nasopharyngitis and hypersensitivity.
For more information, please see the Prescribing Information and Patient Information.
VYEPTI is contraindicated in patients with serious hypersensitivity to eptinezumab-jjmr or to any of the excipients. Reactions have included angioedema.
VYEPTI is indicated for the preventive treatment of migraine in adults.
Hypersensitivity reactions: Hypersensitivity reactions, including angioedema, urticaria, facial flushing, and rash, have occurred with VYEPTI in clinical trials. Most hypersensitivity reactions occurred during infusion and were not serious, but often led to discontinuation or required treatment. Serious hypersensitivity reactions may occur. If a hypersensitivity reaction occurs, consider discontinuing VYEPTI, and institute appropriate therapy.
The most common adverse reactions (≥2% and at least 2% or greater than placebo) in the clinical trials for the preventive treatment of migraine were nasopharyngitis and hypersensitivity.
For more information, please see the Prescribing Information and Patient Information.